Dainippon, SanBio Call Time On Stroke Cell Therapy Alliance
SanBio To Press On Despite Trial Failure
Executive Summary
Japanese companies agree to discontinue regenerative cell therapy pact after high-profile Phase II failure, but SanBio will move ahead with development and Dainippon will hold onto ex-partner stake for now.
You may also be interested in...
Five Topics That Shaped Japan Pharma In 2019
Looking back on the top stories about Japan in Scrip and the Pink Sheet over 2019, it is hard to avoid the continued dominance of corporate transactions - in particular those involving Takeda.
Deal Watch: Roche Partners With Rheos To Develop Novel Immunometabolism Therapeutics
Roche will obtain options to license candidates discovered and optimized by Rheos under the collaboration. Jazz acquires US rights to PharmaMar SCLC candidate, while Biogen teams with both Ionis and Catalyst.
Gene Therapy 'Vant' Unveiled As Dainippon, Roivant Finalize $3bn Deal
Japanese firm signs definitive agreement to acquire Roivant's interests in five 'vants' initially, including new gene therapy operation, as ex-Genentech president named head of new entity.